Identity recordFDA-reviewed unapproved peptide identity
What KPV resolves to
KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.
- Evidence lane
- FDA-reviewed unapproved peptide identity
- Current record
- No FDA-approved KPV drug and no identified human administration study
- Checked
- July 20, 2026
Lys-Pro-Vallysine-proline-valineMSH 11-13alpha-MSH 11-13KPV peptide
Destination recordPemeriksaan produk BPOM dan distribusi wajib
What Indonesia still has to prove
Panduan Indonesia untuk mencocokkan klaim produk terkait peptida di Cek BPOM dan memeriksa bukti distribusi farmasi yang tersertifikasi, masih berlaku, atau telah dicabut melalui catatan CDOB publik sebelum menilai penjual, produk impor, pasar daring, bahan riset, atau jalur pasok.
- Comparison mode
- Rupiah / catatan produk BPOM dan distribusi CDOB
- Price coverage
- Belum ada tabel penjual Indonesia yang memenuhi syarat
- Guide updated
- 18 Juli 2026